4CPS-110 Safety and effectiveness of obinutuzumab in chronic lymphocytic leukaemia: our experience

Abstract

were: gender, age, wild or mutated BRAF, dose reductions, start date, adverse effects, progression and death date.The Kaplan-Meier method was used to analyse PFS and OS. Statistical analysis was made with STATA.14. Results There were 14 men and 18 women receiving the combination. Median age was 59.4 years (range 34.4-82.7) and V600-BRAF was mutated in all patients.Most of the patients left the treatment, and only six are still receiving it. Patients that discontinued the treatment were 25 due to progression and two due to adverse effects. The median PFS is 7.38 months (95% CI: 5.51 to 11.44). During the study, 13 patients died. The median OS is 16.23 months (95% CI: 14.52 to not reached).Many adverse effects appeared with this combination and 38% of the patients had to reduce dose due to toxicity. Most common side effects were: fever, dermatologic effects (such as eczema, rash, oedemas), neurological toxicity (such as cephalea, confusion, dizziness, loss of memory), visual alterations (photophobia, visual reduction) and asthaenia. Conclusion Dabrafenib and trametinib are a good alternative for patients diagnosed with metastatic melanoma with BRAF mutation. Despite the toxicity, this is a serious conditioning for patients' life, and the results of PFS and OS are significant for patients without other options for years. More studies comparing dabrafenib and trametinib with other therapies in advanced melanoma, such as immunotherapy, are required to choose the best option for treating patients.